Pfizer to invest $465 million in sterile injectables facility 30th July 2018
Pfizer has announced plans to invest $465 million to build a sterile injectable pharmaceutical production facility in Portage, Michigan, USA. The new 400,000-square-foot production facility will expand Pfizer’s presence in Portage, where the company employs more than 2,200 people at one of its largest plants.
“This investment is part of our overall plan announced in January to invest approximately $5 billion in US-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act,” said Ian Read, Chairman and Chief Executive Officer, in a company statement last week. “During the next 6years, we expect to invest approximately $1.1 billion in Kalamazoo County—which is in addition to the $1 billion we have invested in the site over the past decade.”
This new modular aseptic processing facility will incorporate aseptic manufacturing equipment, systems and design, including multiple, self-contained modular manufacturing lines. Pfizer says groundbreaking is planned for the spring 2019, with construction expected to be completed in 2021. After the facility is validated by regulatory agencies, production should begin in 2024, according to the company.
Pfizer’s Portage site is a global supplier of sterile injectable, liquids and semi-solid medicines, and active pharmaceutical ingredients, producing more than 150 products.